Core Insights - Outset Medical, Inc. reported a 6% increase in revenue for Q1 2025, reaching $29.8 million compared to $28.2 million in Q1 2024, driven by strong performance in product and service revenues [4][9] - The company continues to demonstrate operational improvements, with a significant reduction in operating expenses by 39% year-over-year, contributing to a path toward profitability [6][11] - The installed base of the Tablo system is growing, with a notable increase in recurring revenue from consumables and services, which rose by 20% to $22.7 million [3][4][9] Financial Performance - Product revenue increased by 4% to $21.3 million, while service and other revenue grew by 9% to $8.5 million compared to the same period last year [4] - Gross profit for Q1 2025 was $11.1 million, a 35% increase from $8.2 million in Q1 2024, with gross margin improving to 37.2% from 29.2% [5][9] - The net loss narrowed to $25.8 million, or ($3.66) per share, compared to a net loss of $39.9 million, or ($11.77) per share in the prior year [8][9] Operational Highlights - The company shipped its 3 millionth Tablo treatment during the quarter, marking a significant milestone with 1 million treatments added over the past year [9] - Operating expenses were reduced to $27.5 million from $45.1 million in Q1 2024, with R&D expenses at $5.5 million, S&M expenses at $13.7 million, and G&A expenses at $8.3 million [6][8] - Non-GAAP operating expenses were reported at $24.6 million, reflecting ongoing efforts to streamline operations [7] Cash Position and Guidance - Total cash, including restricted cash and short-term investments, was $192 million as of March 31, 2025, following a financing round that provided approximately $210 million in cash [10][25] - The company reiterated its 2025 revenue guidance of $115 million to $125 million and expects to use less than $50 million in cash for the year, a significant reduction from $103 million used in 2024 [11]

Core Insights - Osisko Metals has announced new drilling results from the Gaspé Copper Project, confirming the potential for resource expansion both at depth and to the south of the current deposit [1][4][10] Drilling Results - Drill hole 30-1065 intersected 323.0 metres averaging 0.43% Cu and 3.18 g/t Ag, with a higher-grade section of 13.3 metres averaging 2.50% Cu and 17.8 g/t Ag [5] - Drill hole 30-1061 extended mineralization to a vertical depth of 712 metres, with significant intersections of 172.5 metres averaging 0.18% Cu and 1.52 g/t Ag, and 215.5 metres averaging 0.31% Cu and 2.67 g/t Ag [5] - Drill hole 30-1064 extended mineralization to a vertical depth of 618 metres, with intersections of 164.7 metres averaging 0.26% Cu and 1.94 g/t Ag [5] - Drill hole 30-1067, located 215 metres south of the 2024 MRE model, intersected 136.8 metres averaging 0.32% Cu and 3.18 g/t Ag, indicating that mineralization remains open to the south [5][6] Geological Insights - The new drilling results support a revised geological model, with mineralization occurring as disseminations and veinlets of chalcopyrite, primarily controlled stratigraphically [7][9] - The current drilling program aims to convert the November 2024 Mineral Resource Estimate (MRE) to Measured and Indicated categories and to explore deeper stratigraphy [11][10] Resource Estimates - The Gaspé Copper Project currently has Indicated Mineral Resources of 824 million tonnes averaging 0.34% CuEq and Inferred Mineral Resources of 670 million tonnes averaging 0.38% CuEq [16] - The project hosts the largest undeveloped copper resource in eastern North America, strategically located near existing infrastructure [16]

Group 1 - Outset Medical, Inc. (OM) shares have increased by 9.6% in the past four weeks, closing at $11.01, with a mean price target of $18.90 indicating a potential upside of 71.7% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $14.91, where the lowest estimate is $7.50 (31.9% decline) and the highest is $45 (308.7% increase) [2] - Analysts show strong agreement on OM's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 80.8% over the past month, with two estimates increasing and no negative revisions [12] - OM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]

SAN JOSE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter 2025 after the close of trading on Wednesday, May 7, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer ...

Robert Wares, Osisko Metals CEO, commented: "We are very pleased with these new drill results at Gaspé, which have exceeded our expectations. All holes intersected significant disseminated mineralization within the volume of the 2024 MRE model, and new mineralization has been added at depth well below the base of the 2024 MRE model, which was constrained to the lower contact of the C Zone skarn horizon. Drill core from historical hole 30-947 was also recovered and assayed, yielding positive results and indi ...

Outset Medical, Inc. (OM) closed the last trading session at $10.91, gaining 15.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.49 indicates an 188.6% upside potential.The average comprises five short-term price targets ranging from a low of $7.50 to a high of $45, with a standard deviation of $18.67. While the lowest estimate indicates a decline of 31.3% from the current pr ...

Core Viewpoint - Outset Medical, Inc. has announced a one-for-fifteen reverse stock split, effective March 20, 2025, to reduce the number of outstanding shares and potentially enhance the stock's marketability [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split was approved by stockholders on March 5, 2025, and will convert every 15 pre-split shares into one new share, reducing the total from approximately 265 million to about 17 million shares [2]. - The reverse stock split will not change stockholders' percentage ownership interests, except for fractional shares, which will be compensated with cash payments [3]. - The number of shares available under the Company's equity incentive plans and the exercise prices of outstanding options will be proportionately adjusted [4]. Group 2: Administrative Aspects - Equiniti Trust Company, LLC will act as the transfer agent for the reverse stock split, managing the issuance of post-split shares in a paperless format without requiring action from stockholders [5]. - Registered stockholders will automatically receive post-split shares, while those holding shares in "street name" will have their positions adjusted accordingly [5]. Group 3: Company Overview - Outset Medical is focused on pioneering technology to reduce the cost and complexity of dialysis, with its Tablo® Hemodialysis System representing a significant advancement in the field [7]. - The Tablo system allows for flexible dialysis delivery, integrating water purification and on-demand dialysate production, and is designed to enhance patient care and operational efficiency [7].

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39513 Outset Medical, Inc. (Exact name of Registrant as specified in its Charter) Delaware 20-0514392 (State or other jurisdiction of ...

Core Viewpoint - Outset Medical, Inc. (OM) has shown a downtrend recently, losing 9.9% over the past week, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging to counteract selling pressure [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, suggesting that selling pressure may be subsiding, which could lead to a bullish trend for the stock [2][4]. - A hammer pattern forms when there is a small difference between opening and closing prices, with a long lower wick, indicating that the stock has found support after hitting a new low during a downtrend [3][4]. - The effectiveness of the hammer pattern is contingent on its placement on the chart and should be used alongside other bullish indicators for confirmation [5]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for OM, which is a bullish indicator, as it typically correlates with price appreciation in the near term [6]. - The consensus EPS estimate for the current year has increased by 1% over the last 30 days, reflecting analysts' agreement on the company's potential for better earnings than previously predicted [7]. - OM holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, indicating strong potential for outperformance in the market [8].

Core Viewpoint - In 2025, Bitcoin has underperformed expectations, struggling to maintain its value above $100,000, with only a 5% increase for the year, prompting investors to seek alternative cryptocurrencies that may outperform Bitcoin [1]. Group 1: Alternative Cryptocurrencies - XRP has increased over 400% since the presidential election and 30% in 2025, benefiting from a pro-crypto regulatory environment under the Trump administration, with potential resolution of regulatory issues from the SEC [3][4]. - XRP is speculated to be a candidate for a new spot ETF approval, with current trading around $2.70 and price predictions reaching as high as $10, depending on investor interest in ETFs [5]. - Bittensor has a market cap of nearly $4 billion and is up 3% for the year, focusing on AI projects and recently listed on Coinbase, which boosted its price by 20% [6][8]. - Bittensor has a limited supply of 21 million coins, similar to Bitcoin, contributing to its high price of $450 due to scarcity [9]. - Mantra has seen a 99% increase year-to-date and an astonishing 43,927% since October 2023, focusing on real-world asset tokenization for financial institutions [10][11]. - The asset tokenization market is projected to be a multitrillion-dollar opportunity by 2030, with significant potential for growth in various asset classes [13][14]. Group 2: Market Context - Despite Bitcoin's strong historical performance, XRP, Bittensor, and Mantra are positioned to potentially deliver substantial gains over the next five years, although they carry higher risks [15].